News

Agrospheres Completes Expansion of $25 Million Series B Round

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection, today announced the closing of its Series B funding round with a strategic investment from FMC Corporation (NYSE: FMC), a global leader in agriculture sciences. This investment brings the total funding in AgroSpheres’ Series B round to $25 million, demonstrating the strong confidence in the company’s innovative solutions. FMC Ventures joins Lewis and Clark AgriFood, Ospraie Ag Science, BIDRA Ventures, and Cavallo Ventures to close out the round.

AgroSpheres has developed cutting-edge technology that enables precise delivery of active ingredients such as small molecules, peptides, and nucleic acids in crop protection products. This technology has the potential to revolutionize the agriculture industry by improving the efficiency, efficacy, and sustainability of crop protection practices.

“We are excited to invest and partner with AgroSpheres, sharing a common vision for advancing agriculture,” said Mark Brooks, managing director, FMC Ventures. “Their innovative technology has the potential to be a game changer in crop protection. With broad IP protection, manufacturing capabilities, and a strong industry network, AgroSpheres stands out in AgTech. We believe this investment will drive innovation and accelerate the development of sustainable solutions for farmers globally.”

AgroSpheres’ Co-Founder and CEO, Payam Pourtaheri, also commented on the investment, saying, “We are honored to welcome FMC Corporation as a strategic investor in AgroSpheres. Their extensive expertise in agricultural sciences and global reach make them an ideal partner for us. This investment will further empower us to continue our mission of providing more effective and sustainable solutions for the agricultural industry. Together with FMC, we will strive to make a significant impact on global agriculture.”

AgroSpheres has gained recognition for its innovative approach to precision delivery of crop protection products, reducing environmental impact, and enhancing overall crop health. This latest investment will support the company in its mission to bring this technology to more markets, helping farmers worldwide address the challenges of feeding a growing global population while minimizing the environmental footprint.

Recent News

11/08/2024

Catalyzing Crucial Cross-Border Collaborations and Innovation to Address Unmet Needs in Rare Diseases

The World Health Organization (WHO) defines a rare disease (RD), or orphan disease, as affecting fewer than 65 per 100,000 people. Although individual RDs are uncommon, collectively, over 10,000 rare diseases impact about 400 million people globally—roughly 5% of the world’s population. Almost 95% of these diseases remain without a single approved treatment. Orphan drugs

11/05/2024

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical,

10/29/2024

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer. Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With